10.0
Superb
Client Ratings
Not yet reviewed
Overview
Practice Areas
|
-
40% Administrative Law
17 years, 20 cases
-
40% Life Sciences / Biotechnology
17 years, 20 cases
-
20% Health Care
17 years, 20 cases
|
Contact Information
|
|
About Me
Photos (0)
Videos (0)
|
About me: James Czaban is the Chairman of the FDA Department at WilmerHale. Mr. Czaban's practice focuses on providing legal, regulatory and legislative counseling to... more
|
References
Client Reviews
|
How would you rate this lawyer?
If you're a current or former client, share your thoughts (anonymously, if you prefer). Would you recommend this lawyer to other clients?
Review this lawyer
|
Endorsements
|
Jim is a superior lawyer in every sense. His knowledge of FDA and administrative practice is unparalled. Jim provides his clients with exemplary...
more
Endorsement from lawyer:
John Isacson
, Washington (DC), About 1 year ago
|
Résumé
Licenses
|
-
15 years
since James Nicholas O'Neil Czaban was first licensed to practice law in NY.
-
11 years
since James Nicholas O'Neil Czaban was first licensed to practice law in DC.
We have not found any instances of professional misconduct for this lawyer.
|
Work Experience
|
| Position |
Duration |
| Shareholder at Heller Ehrman LLP |
2001–2006
|
| Partner at Venable, LLP |
2001–2001
|
| Associate at Venable, LLP |
1996–2000
|
| Attorney at Bass & Ullman, P.C. |
1993–1996
|
See all 4 job entries
Hide additional positions
|
Education
|
|
Awards
|
| Award Name |
Granting Organization |
Date |
| FDA Practice Ranked in Regulatory Super League |
Practical Law Company (PLC) |
2007 |
| Life Sciences Practice Ranked in Cross-Border Super League |
Practical Law Company (PLC) |
2007 |
| Nationally Ranked Practice Group -- FDA Regulatory |
Chambers and Partners |
2007 |
| Top Lawyer, Food & Drug Law |
Washingtonian Magazine |
2004 |
See all 4 awards
Hide additional awards
|
Associations
|
| Position |
Association Name |
Duration |
| Admitted to Practice |
Virginia State Bar |
1992–present
|
| Admitted to Practice |
New York State Bar Association |
1995–present
|
| Lecturer |
Food and Drug Law Institute |
1996–present
|
| Admitted to Practice |
District of Columbia Bar |
1998–present
|
| Member |
Professional organizations and associations |
2001–present
|
| Legal Writing Awards Committee, Member and Chairman. |
Food and Drug Law Institute |
2002–present
|
| Audit Committee Member |
Food and Drug Law Institute |
2005–present
|
See all 7 association entries
Hide additional associations
|
Portfolio
Publications
|
See all 9 publications
Hide additional publications
|
Speaking Engagements
|
| Speaking Engagement Name |
Conference |
Date |
| Repositioning Old Drug Products for New Markets |
BIO 2007 Annual Meeting |
2007 |
| Follow-On Proteins -- Legislative and Regulatory Update |
BayBio 2007 Annual Meeting |
2007 |
| 10 Regulatory Mistakes Early Stage Biotech Companies Make and How to Avoid Them |
MPM Capital Annual Healthcare Conference |
2007 |
| Lifecycle Management Strategies For Drug and Biotechnology Companies |
RAPS Horizons Conference |
2007 |
| The Competitive Conundrum of "Authorized Generics" |
Seton Hall Law School/NJIPLA -- Regulatory Developments for Pharmaceutical Companies |
2007 |
| Follow-On Biologics -- What Does The Future Hold? |
AIPLA Annual Conference |
2006 |
| Developments in Drug Safety Regulation |
FDLI Annual Educational Conference |
2006 |
| FDA Regulation of Pharmaceuticals and Biologics |
FDLI's Fundamentals of Food & Drug Regulation |
2006 |
| Deciphering Section 505(b)(2) NDAs |
Harvard University -- Second Annual FDA Regulatory and Compliance Symposium |
2006 |
| FDA Update: New Developments, and Outlook for Change Under the Democrat Congress |
Silicon Valley Association of General Counsel 18th Annual All Hands Meeting |
2006 |
| Regulation and Marketing of Natural Products In The United States |
Australian Natural Products Industry Meeting |
2004 |
| Balancing Innovation and Competition In the U.S. Pharmaceutical Market |
ABA Administrative Law Conference |
2003 |
See all 12 speaking engagements
Hide additional speaking engagements
|
|
